TReatment Approaches and bIomarkers preValence in bladdEr Cancer in RuSsian Federation
← catalyst calendarNCT07038928 · readout in 134 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
600estimated
Sites
20
Country
Russia
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-06-30 | actual | When the study began enrolling |
| Primary completion | 2026-12-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-12-31 | estimated | The whole study's end, after follow-up |
| First posted | 2025-06-26 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Bladder Cancer
Primary outcomes
what the primary-completion date above is the date OFProportion of patients receiving any intravesical treatment among patients with high-risk NMIBC
measured 24 months
Proportion of patients receiving intravesical chemotherapy among patients with high-risk NMIBC
measured 24 months
Proportion of patients receiving intravesical BCG treatment among patients with high-risk NMIBC
measured 24 months
Proportion of patients receiving any intravesical treatment among patients with non-high-risk NMIBC
measured 24 months
Proportion of patients receiving intravesical chemotherapy among patients with non-high-risk anamnestic NMIBC
measured 24 months
Proportion of patients receiving intravesical BCG treatment among patients with non high-risk anamnestic NMIBC
measured 24 months
Proportion of patients without intravesical NMIBC treatment
measured 24 months
Number of relapses in high risk NMIBC patients (ongoing and anamnestic) overall and by each treatment regimen
measured 24 months
Number of relapses in non-high risk NMIBC patients overall and by each treatment regimen, intravesical BCG
measured 24 months
Time to first relapse of NMIBC
measured 24 months
Proportion of patients receiving neoadjuvant treatment among patients with MIBC
measured 24 months
Rate of pathologic complete response among MIBC patients receiving neoadjuvant treatment
measured 24 months
Proportion of MIBC patients not received neoadjuvant treatment before radical cystectomy
measured 24 months
Proportion of patients received adjuvant treatment among patients with MIBC
measured 24 months
Proportion of MIBC patients (anamnestic) received trimodal therapy
measured 24 months
Time to progression to mBC from NMIBC and MIBC
measured 24 months
Type of progression to mBC from NMIBC and MIBC
measured 24 months
Proportion of patients with locoregional progression after cystectomy
measured 24 months
Proportions of patients receiving systemic treatment regimens within first-line therapy among patients with mBC
measured 24 months
Proportion of patients with progression on first line mBC treatment
measured 24 months
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed